Table 3. Main characteristics of clinical trials of epigenetic inhibitors in SCLC.
| ClinicalTrials.gov identifier | Design | Patient | Therapy | Status |
|---|---|---|---|---|
| NCT02489903 (QUADRUPLE THREAT) (141) | Phase 2, RCT, OL, PA | Refractory SCLC | Arm 1: RRx-001 + EP | Completed |
| Arm 2: EP | ||||
| NCT03699956 (REPLATINUM) (142) | Phase 3, RCT, OL | SCLC | Arm 1: RRx-001 + EP | Ongoing |
| Arm 2: EP | ||||
| NCT03879798 | Phase 1/2, OL, NR | Relapsed SCLC | DS-3201b + Irinotecan | Ongoing |
| NCT02223052 | Phase 1, RCT, OL, PA, Multicenter | SCLC | CC-486 (Oral Azacitidine) or Vidaza (Azacitidine for Injection) | Ongoing |
| NCT02712905 | Phase 1/2, SA, OL, NR | Advanced drug-resistant SCLC | INCB059872 ± nivolumab | Ongoing |
| NCT03913455 | Phase 2, SA, OL | ED-SCLC | Guadecitabine + Carboplatin | Ongoing |
ED, extensive disease; EP, etoposide plus either cisplatin or carboplatin; NR, non-randomized; OL, open-label; PA, parallel assignment; RCT, randomized controlled trial; SCLC, small cell lung cancer; SA, single arm.